Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) EBIT (2016 - 2025)

Historic EBIT for Marker Therapeutics (MRKR) over the last 10 years, with Q3 2025 value amounting to -$2.1 million.

  • Marker Therapeutics' EBIT rose 1096.5% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.9 million, marking a year-over-year decrease of 4583.83%. This contributed to the annual value of -$11.1 million for FY2024, which is 2374.95% up from last year.
  • Per Marker Therapeutics' latest filing, its EBIT stood at -$2.1 million for Q3 2025, which was up 1096.5% from -$4.3 million recorded in Q2 2025.
  • In the past 5 years, Marker Therapeutics' EBIT ranged from a high of -$2.1 million in Q3 2025 and a low of -$9.8 million during Q1 2022
  • Its 4-year average for EBIT is -$4.0 million, with a median of -$3.9 million in 2024.
  • In the last 5 years, Marker Therapeutics' EBIT soared by 5600.21% in 2023 and then crashed by 8461.49% in 2025.
  • Quarter analysis of 4 years shows Marker Therapeutics' EBIT stood at -$3.0 million in 2022, then grew by 3.32% to -$2.9 million in 2023, then tumbled by 31.44% to -$3.9 million in 2024, then surged by 44.66% to -$2.1 million in 2025.
  • Its EBIT stands at -$2.1 million for Q3 2025, versus -$4.3 million for Q2 2025 and -$4.6 million for Q1 2025.